title: Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves.
abstract: We report a case of acute hepatitis of autoimmune origin which occurred in a 43-yr-old woman during iv glucocorticoid (GC) pulse therapy for Graves' ophthalmopathy (GO). Prior to therapy, liver function tests were normal with no previous history of liver disorders or conditions predisposing to GC-associated liver damage. After the administration of a 4.7-g cumulative dose of methylprednisolone acetate, there was a marked increase of liver enzymes, prompting immediate discontinuation of iv GC. Nevertheless, liver enzymes increased further, reaching a peak 45 days later, with values 30- to 50-fold greater than those prior to therapy, associated with evidence of impaired liver function. Liver biopsy showed a marked lymphocytic infiltration, likely indicating an autoimmune hepatitis. Based on the assumption that following GC-induced immune suppression, autoimmune hepatitis might have been precipitated by sudden re-activation of the immune system during interpulse periods, we treated the patient with im and then oral GC, in order to re-induce immune suppression. Within three days from re-institution of GC therapy, there was a marked reduction of liver enzymes and amelioration of liver function. Complete normalization was achieved two months later, while the patient was still receiving a low maintenance dose of oral prednisone.
authors.affiliation: Department of Endocrinology, University Hospital of Pisa, Pisa, Italy. m.marino@endoc.med.unipi.it
authors.forename: M
authors.initials: M
authors.lastname: Marinò
authors.forename: E
authors.initials: E
authors.lastname: Morabito
authors.forename: M A
authors.initials: MA
authors.lastname: Altea
authors.forename: E
authors.initials: E
authors.lastname: Ambrogini
authors.forename: F
authors.initials: F
authors.lastname: Oliveri
authors.forename: M R
authors.initials: MR
authors.lastname: Brunetto
authors.forename: L E
authors.initials: LE
authors.lastname: Pollina
authors.forename: D
authors.initials: D
authors.lastname: Campani
authors.forename: P
authors.initials: P
authors.lastname: Vitti
authors.forename: L
authors.initials: L
authors.lastname: Bartalena
authors.forename: A
authors.initials: A
authors.lastname: Pincheral
authors.forename: C
authors.initials: C
authors.lastname: Marcocci
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use*; D006111:Graves Disease / Q000150:complications* / Q000188:drug therapy* / Q000532:radiotherapy; D019693:Hepatitis, Autoimmune / Q000209:etiology*; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000473:pathology; D008111:Liver Function Tests; D008214:Lymphocytes / Q000502:physiology; D008775:Methylprednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011241:Prednisone; D008775:Methylprednisolone